Alirocumab


( Last Updated : December 7, 2015)
Generic Name:
Alirocumab
Project Status:
Complete
Therapeutic Area:
Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia
Manufacturer:
Sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Praluent
Project Line:
Reimbursement Review
Project Number:
SR0469-000
Call for patient/clinician input closed:

Details


Submission Type:
Initial
Indications:
Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation: